Recent test results from Shire's CUVITRU show the treatment has performed well in helping those whose immune system is not complete or do not work as it should.
Those who have an immunodeficiency disease have tougher times battling diseases, according to a press release. There are over 300 such diseases.
The Food and Drug Administration approved CUVITRU in September 2016. CUVITRU is part of Shire's line of treatments that use the immune system to attack virus and bacteria cells. The use of CUVITRU can be modified depending on how a doctor and patient want to use it to manage immunodeficiency disease.
According to the test results, after a year, those who were given CUVITRU said that they were much happier with the outcomes of the CUVITRU in two categories on the Life Quality Index compared to taking the medicines that used the immune system to attack virus and bacteria cells before CUVITRU testing.
CUVITRU can be used in the United States and Switzerland.